0000000000283238

AUTHOR

Simona Malucchi

showing 11 related works from this author

MSJ872889_supplemental_table – Supplemental material for Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

2019

Supplemental material, MSJ872889_supplemental_table for Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience by Chiara Zecca, Francesca Bovis, Giovanni Novi, Marco Capobianco, Roberta Lanzillo, Jessica Frau, Anna Maria Repice, Bahia Hakiki, Sabrina Realmuto, Simona Bonavita, Erica Curti, Laura Brambilla, Giorgia Mataluni, Paola Cavalla, Alessia Di Sapio, Elisabetta Signoriello, Stefania Barone, Giorgia T Maniscalco, Ilaria Maietta, Isabella Maraffi, Giacomo Boffa, Simona Malucchi, Agostino Nozzolillo, Giancarlo Coghe, Claudia Mechi, Giuseppe Salemi, Antonio Gallo, Rosaria Sacco, Maria Cellerino, Maria Malentacchi, Marcello De Angelis, Lorena Lorefice, Elia…

FOS: Clinical medicine111702 Aged Health CareFOS: Health sciences110904 Neurology and Neuromuscular Diseases
researchProduct

Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

2020

Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS). Objective: To investigate the effectiveness and safety of rituximab in relapsing–remitting (RR) and progressive MS. Methods: This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed. Results: A total of 355/451 enrolled subjects had at least one follow-up visit an…

Multiple Sclerosismedicine.drug_classLymphocyte depletionrelapsing–remittingMonoclonal antibodyPrimary progressive03 medical and health sciences0302 clinical medicineMultiple Sclerosis Relapsing-Remittingreal lifemedicineHumansImmunologic Factors030212 general & internal medicineSecondary progressiveRetrospective Studiesprimary progressivebusiness.industryMultiple sclerosisRituximab; multiple sclerosis; primary progressive; real life; relapsing–remitting; secondary progressiveTreatment optionsmedicine.diseaseNeurologyRelapsing remittingItalymultiple sclerosiImmunologysecondary progressiveRituximabSettore MED/26 - NeurologiaNeurology (clinical)businessRituximab030217 neurology & neurosurgerySwitzerlandmedicine.drug
researchProduct

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

2015

Introduction Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease reactivation. Currently no disease-modifying drug (DMD) has been shown to be able to abolish disease reactivation. The aims of the current study were: (1) to determine the frequency of MS reactivation after NTZ discontinuation; (2) to evaluate predictors of reactivation risk, and (3) to compare the effect of different treatments in reducing this risk. Methods Data from 132 patients with MS followed-up for 2 years before NTZ treatment and 1 year after interruption were collected from two Italian MS centers and retrospectively evaluated. Results Overall, 72 of 132 patients (54.5%) had relapses af…

medicine.medical_specialtyNeurologyNatalizumab discontinuationDiseasePharmacologyMultiple sclerosisNatalizumabInternal medicineparasitic diseasesDisease reactivationmedicineMultiple sclerosiIn patientFirst-line therapieOriginal ResearchDisease reactivation; First-line therapies; Multiple sclerosis; Natalizumab discontinuation; Rebound; Second-line therapies; Neurology (clinical); NeurologyFirst-line therapiesReboundSecond-line therapiebusiness.industryMultiple sclerosisRetrospective cohort studymedicine.diseaseDiscontinuationNeurologyTreatment strategyNeurology (clinical)businessSecond-line therapiesmedicine.drug
researchProduct

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

2022

Background and ObjectivesSeveral studies have assessed risk factors associated with the severity of COVID-19 outcomes in people with multiple sclerosis (PwMS). The potential role of disease-modifying therapies (DMTs) and demographic and clinical factors on the risk of acquiring SARS-CoV-2 infection has not been evaluated so far. The objective of this study was to assess risk factors of contracting SARS-CoV-2 infection in PwMS by using data collected in the Italian MS Register (IMSR).MethodsA case-control (1:2) study was set up. Cases included PwMS with a confirmed diagnosis of COVID-19, and controls included PwMS without a confirmed diagnosis of COVID-19. Both groups were propensity score–m…

AdultMaleMultiple SclerosisTime Factors41Dimethyl FumarateSex FactorRelapsing-RemittingSeverity of Illness IndexArticleImmunosuppressive AgentSex FactorsMultiple Sclerosis Relapsing-RemittingRisk FactorsMultiple SclerosiOdds RatioHumansAge Factor36053g COVID-19Fingolimod HydrochlorideSARS-CoV-2NatalizumabRisk FactorAge FactorsCOVID-19Glatiramer AcetateInterferon-betaMiddle AgedMultiple Sclerosis Chronic Progressive323Chronic ProgressiveNeurologyItalyCase-Control StudiesAdult; Age Factors; COVID-19; Case-Control Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time FactorsFemaleNeurology (clinical)Case-Control StudieImmunosuppressive AgentsHuman
researchProduct

A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.

2013

Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage (%) of 21 relapses resulting in a …

MalePediatricsNeurologyCross-sectional studymulti center studyAdrenal Cortex HormoneAdrenal Cortex HormonesRecurrenceSurveys and QuestionnairesMultiple SclerosiCorticosteroidSurveys and QuestionnaireRelapseSurveyNeuroradiologyGeneral MedicineMiddle AgedManagementPsychiatry and Mental healthMethylprednisoloneItalyNeurologyPsychiatry and Mental Healthmultiple sclerosiSettore MED/26 - NeurologiaFemaleNeurosurgerymedicine.drugHumanAdultmedicine.medical_specialtyMultiple SclerosisDermatologyMethylprednisolonemedicineHumansMedical prescriptionCross-Sectional Studietherapybusiness.industryMultiple sclerosismedicine.diseaseManagement of multiple sclerosisCross-Sectional StudiesHealth Care SurveyHealth Care SurveysPhysical therapyNeurology (clinical)business2708
researchProduct

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

2018

In this independent, multicenter, retrospective study, we investigated the short-term persistence to treatment with first-line self-injectable or oral disease-modifying treatments (DMTs) in patients with relapsing–remitting multiple sclerosis. Data of patients regularly attending 21 Italian MS Centres who started a self-injectable or an oral DMT in 2015 were collected to: (1) estimate the proportion of patients discontinuing the treatment; (3) explore reasons for discontinuation; (3) identify baseline predictors of treatment discontinuation over a follow-up period of 12 months. We analyzed data of 1832 consecutive patients (1289 women, 543 men); 374 (20.4%) of them discontinued the prescrib…

MaleInjectionTime FactorsPatient Dropoutdisease-modifying therapies; multiple sclerosis; outcome measurement; persistence to treatment; quality of lifeAdministration OralSelf AdministrationSex FactorKaplan-Meier EstimateRelapsing-Remittingmultiple sclerosisImmunologic Factor0302 clinical medicineQuality of lifeRetrospective StudieRisk FactorsMedicine030212 general & internal medicineDisease-modifying therapiedisease-modifying therapiesDisease-modifying therapies Multiple sclerosis Outcome measurement Persistence to treatment Quality of life Administration Oral Adult; Female Follow-Up Studies Humans Immunologic Factors Injections Kaplan-Meier EstimateMale Multiple Sclerosis Relapsing-Remitting Patient Dropouts Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Self Administration Sex Factors Time FactorsHazard ratioPrognosisNeurologyTolerabilityAdministrationSettore MED/26 - NeurologiaFemaleoutcome measurementHumanOralAdultmedicine.medical_specialtyPatient DropoutsTime FactorPrognosiFollow-Up StudieInjections03 medical and health sciencesRoute of administrationMultiple Sclerosis Relapsing-RemittingSex FactorsInternal medicineHumansImmunologic FactorsMultiple sclerosiAdverse effectProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelRisk FactorRetrospective cohort studyDiscontinuationDisease-modifying therapies; Multiple sclerosis; Outcome measurement; Persistence to treatment; Quality of life; Administration Oral; Adult; Female; Follow-Up Studies; Humans; Immunologic Factors; Injections; Kaplan-Meier Estimate; Male; Multiple Sclerosis Relapsing-Remitting; Patient Dropouts; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Self Administration; Sex Factors; Time Factorsquality of lifeProportional Hazards Modelpersistence to treatmentNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of neurology
researchProduct

Informing MS patients on treatment options: a consensus on the process of consent taking

2020

Abstract\ud In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process.\ud Aims\ud The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice.\ud Results\ud The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the…

medicine.medical_specialtyConsensusProcess (engineering)media_common.quotation_subjectDermatologyDisease modifying treatment; Informed consent; Multiple sclerosisMultiple sclerosis03 medical and health sciences0302 clinical medicineResource (project management)Informed consentDisease modifying treatmentmedicineHumans030212 general & internal medicineInformed consentEmpowermentmedia_commonPhysician-Patient Relationsbusiness.industryTreatment optionsGeneral MedicineClinical PracticePsychiatry and Mental healthItalyFamily medicineDisease modifying treatment; Informed consent; Multiple sclerosis; Consensus; Humans; Italy; Physician-Patient Relations; Informed Consent; Multiple SclerosisSettore MED/26 - NeurologiaNeurology (clinical)Decision processbusiness030217 neurology & neurosurgery
researchProduct

Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.

2022

ObjectiveAssessing the risk of clinical and radiological reactivation during pregnancy and post partum in women with multiple sclerosis (MS) treated with natalizumab (NTZ) throughout pregnancy (LONG_EXP) compared with women interrupting treatment before (NO_EXP) and within >−30 days and ≤90 days from conception (SHORT_EXP), and describing newborns’ outcomes.MethodsMaternal clinical and radiological outcomes and obstetric and fetal outcomes were retrospectively collected and compared among groups (NO_EXP, SHORT_EXP, LONG_EXP). Predictors of clinical and radiological reactivation were investigated through univariable and multivariable analysis.Results170 eligible pregnancies from 163 women…

Psychiatry and Mental healthSettore MED/26 - NEUROLOGIAobstetricsmultiple sclerosiobstetricSurgeryNeurology (clinical)MRI; multiple sclerosis; obstetricsSettore MED/26multiple sclerosisMRIJournal of neurology, neurosurgery, and psychiatry
researchProduct

Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian…

2014

Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing-remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment. © Th…

MaleTime FactorsThyroid GlandAutoimmunityAdverse effectmedicine.disease_causemultiple sclerosisGastroenterologythyroidAutoimmunityImmunosuppressive AgentRisk FactorsRetrospective StudiePrevalenceinterferon betaThyroidadverse effects; autoimmunity; glatiramer acetate; interferon beta; thyroid; multiple sclerosisMiddle AgedTreatment Outcomemedicine.anatomical_structureItalyNeurologymultiple sclerosiThyroid autoimmunityCohortFemaleSettore MED/26 - NeurologiaThyroid functionImmunosuppressive AgentsInterferon beta-1aHumanInterferon beta-1bmedicine.drugAdultmedicine.medical_specialtyTime FactorThyroid DiseaseRisk AssessmentYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansGlatiramer acetateAdverse effectRetrospective Studiesbusiness.industryRisk FactorMultiple sclerosisGlatiramer Acetatemedicine.diseaseThyroid DiseasesImmunologyadverse effectsNeurology (clinical)business
researchProduct

Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders

2019

Abstract Objective To evaluate disease activity according to rituximab (RTX) induction and maintenance regimens in a multicenter real-life dataset of NMOSD patients. Methods This is an observational-retrospective multicentre study including patients with NMOSD treated with RTX in 21 Italian and 1 Swiss centers. Demographics, relapse rate and adverse events over the follow-up were summarized taking into account induction strategy (two-1 g infusions at a 15-day interval (IND-A) vs. 375 mg/m2/week infusions for one month (IND-B)) and maintenance therapy (regimen A (M-A) with fixed time-points infusions vs. regimen B (M-B) based on cytofluorimetric driven reinfusion regimens, the least further …

AdultMalemedicine.medical_specialtyMultivariate analysisEfficacyOutcome and Process AssessmentSettore MED/2603 medical and health sciences0302 clinical medicineMaintenance therapyInternal medicinemedicineHumansImmunologic FactorsIn patient030212 general & internal medicineAdverse effectAgedRetrospective StudiesNeuromyelitis opticabusiness.industryMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseaseNeuromyelitis opticaHealth CareRegimenOutcome and Process Assessment Health CareNeurologyEfficacy Neuromyelitis optica RituximabRituximabFemaleNeurology (clinical)businessRituximab030217 neurology & neurosurgerymedicine.drugFollow-Up Studies
researchProduct

mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis

2021

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. A novel coronavirus, namely SARS-CoV-2, has been recently responsible for the highly infectious disease referred as COVID-19, rapidly spreading all over the world. Many vaccines have been developed to control COVID-19 pandemic, including the mRNA vaccines Pfizer/BioNTech (BNT162b2) and Moderna (mRNA1273).1 The vaccination of people with MS (pwMS) has been recommended by several national and international MS societies. However, effectiveness and safety of anti-COVID-19 mRNA vaccines in MS need to be confirmed. The aim of this study was to evaluate the short-term risk of clinical relapses in pwMS in …

Pediatricsmedicine.medical_specialtyeducation.field_of_studyExpanded Disability Status ScaleCoronavirus disease 2019 (COVID-19)business.industryMultiple sclerosisCOVID-19; multiple sclerosis; neuroimmunologyPopulationCOVID-19neuroimmunologymedicine.diseasemultiple sclerosisVaccinationPsychiatry and Mental healthInfectious disease (medical specialty)multiple sclerosiPandemicmedicineSurgeryObservational studymultiple sclerosis neuroimmunology COVID-19Neurology (clinical)businesseducation
researchProduct